EMEA-002468-PIP02-18

Key facts

Active substance
Humanized antibody targeting B cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F
Therapeutic area
Oncology
Decision number
P/0168/2019
PIP number
EMEA-002468-PIP02-18
Pharmaceutical form(s)
Intravenous use
Condition(s) / indication(s)
Treatment of Multiple Myeloma
Route(s) of administration
Solution for infusion
Contact for public enquiries
GlaxoSmithKline Trading Services Limited

Tel. +44 (0)20 8990 3650
E-mail: eu.paediatric-plans@gsk.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating